Intranasal delivery systems for traumatic brain injury: Advancements and perspectives

Area of Science:

• Neuroscience
• Pharmacology
• Biomedical Engineering

Background:

• Traumatic brain injury (TBI) is a significant cause of death and disability, resulting in lasting cognitive, sensorimotor, and personality deficits.
• Current neuroprotective drugs show limited clinical success despite promising preclinical results.
• The blood-brain barrier restricts effective drug delivery to the brain.

Purpose of the Study:

• To review current advancements in intranasal delivery systems for treating traumatic brain injury (TBI).
• To highlight the potential of intranasal delivery as a safe and effective therapeutic strategy for TBI.
• To discuss future clinical perspectives and emerging trends in TBI treatment via intranasal routes.

Main Methods:

• Review of current literature on TBI and intranasal drug delivery systems.
• Analysis of preclinical studies (in vitro and in vivo animal models) on intranasal delivery of molecules and cells for TBI.
• Examination of clinical perspectives and future trends in TBI therapeutics.

Main Results:

• Intranasal delivery bypasses the blood-brain barrier, providing direct access to brain parenchyma.
• Recent developments show efficacy of intranasal delivery systems in preclinical TBI models.
• Various molecules and cell-based therapies are being investigated for intranasal administration.

Conclusions:

• Intranasal delivery presents a favorable and safe approach for TBI treatment.
• Further research and clinical translation of intranasal delivery systems are crucial for effective TBI therapeutics.
• Emerging trends suggest significant potential for intranasal delivery in managing TBI outcomes.